Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients

Status Completed

Clinical Trial Summary

This Phase I study of sorafenib in high risk hepatocellular cancer patients after liver transplantation will study 24 subjects for about 5 years. Each subject will receive sorafenib for 6 months. Safety and effectiveness on the post transplant, high risk HCC patients will be studied.

Clinical Trial Description

Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor with effects on tumor proliferation and angiogenesis. Sorafenib is approved for the treatment of patients with advanced renal cancer and unresectable hepatocellular carcinoma (HCC). The recommended daily dose of Sorafenib is 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal). Studies of single-agent sorafenib showed treatment was well-tolerated with manageable side effects. The results seen with sorafenib in the Phase III (SHARP) trial suggest that VEGF and RAF kinase inhibition prolong survival in patients with advanced HCC. It is not known whether a drug which is considered primarily cytostatic will be effective in preventing cancer recurrences in the setting of minimal residual disease.

This is a phase I, single center, open-label, dose-escalation study to determine the maximum tolerated dose (MTD) and overall safety profile of daily sorafenib as therapy to prevent HCC recurrence in liver transplant subjects with high-risk HCC. For each subject, the study will consist of two phases: a treatment phase and an extension phase. ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00997022
Study type	Interventional
Source	Columbia University
Contact
Status	Completed
Phase	Phase 1
Start date	May 2009
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03971201` - A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion	Phase 2
Recruiting	`NCT04484636` - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	N/A
Recruiting	`NCT05489250` - The PLATON Network
Completed	`NCT01967823` - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer	Phase 2
Terminated	`NCT00878215` - Clinical Application of Image-Guided Liver Surgery	Phase 2
Completed	`NCT04212286` - Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC	N/A
Recruiting	`NCT05992220` - Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion	Phase 2
Completed	`NCT02073435` - A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Active, not recruiting	`NCT01522937` - A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer	Phase 2
Terminated	`NCT05061537` - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04166240` - Measuring and Improving the Safety of Test Result Follow-Up	N/A
Withdrawn	`NCT02288507` - Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer	Phase 1
Terminated	`NCT03026803` - A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer	Phase 2
Active, not recruiting	`NCT04682847` - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Recruiting	`NCT05100082` - Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
Active, not recruiting	`NCT03195699` - Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	Phase 1
Completed	`NCT02616692` - HCC Patient Preferences in Japan	N/A
Active, not recruiting	`NCT03132792` - AFPᶜ³³²T in Advanced HCC	Phase 1
Not yet recruiting	`NCT06239194` - Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT01849588` - Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C	Phase 4